VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
Valion Bio received an FDA-precedent study protocol from NIAID under an agreement valued at up to $7 million, with the agency fully funding BLA-enabling studies and co-navigating the FDA submission. The partnership significantly de-risks the Animal Rule pathway for Entolimod, allowing the company to redirect approximately $7 million in planned capital toward its second-generation asset, Entolasta.
Key figures
- Deal Value Usd
- 7000000
- Nhp studies
- 42
- Prior gov funding
- $35.6 million
- Human subjects studied
- 300
- Prior investment total
- $140 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.